GPC4 and non-small cell lung adenocarcinoma: Two glioblastoma cell variants isolated from a 75 year old female (SNB-75 cells) and a 67 year old female (SF-295 cells) and a non-small cell lung adenocarcinoma cell variant isolated from a 62 year old male (HOP-92) were therefore either treated with CRISPR/Cas9 GPC4 to disrupt GPC4 gene expression or a control double nickase plasmid with gRNA not targeting any gene (CRISPR control).